打败几率:在一个患有ALK重组肺癌的患者中成功怀孕,接受了alectinib治疗
Nicholas Yeo1,2, Fiona Johnston1, Louise Fay3
1Department of Medical Oncology, Prince of Wales Hospital, Nelune Comprehensive Cancer Centre, Randwick, Australia.
Case reports in medicine
|May 19, 2025
概括
这项案例研究表明,alectinib可以安全地用于怀孕期间管理形淋巴瘤激酶重组的非小细胞肺癌. 精心规划和多学科护理对于母亲和孩子的成功结果至关重要.
科学领域:
- 在瘤学瘤学.
- 生殖医学 生殖医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于针对性治疗的安全性数据有限,怀孕期间对癌基因驱动的非小细胞肺癌 (NSCLC) 的管理具有挑战性.
- 形淋巴瘤激酶 (ALK) 重组NSCLC是一种罕见但在年轻女性中被认可的疾病,包括怀孕期间.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
16.7K
